Synergetics USA Signs New Product Development And Consulting Agreement With Retinal Solutions, LLC
Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that
designs, manufactures, and markets innovative devices for ophthalmic and
neurosurgical applications, today announced that it signed a product
Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative devices for ophthalmic and neurosurgical applications, today announced that it signed a product development and consulting agreement with Retinal Solutions, LLC located in Michigan. Retinal Solutions is led by Michael T. Trese, M.D., Antonio Capone, Jr., M.D., and Kimberly Drenser, PhD., M.D., recognized global leaders in the surgical treatment and research of retinal disease with a focus on pediatrics. “We will be working with Drs. Trese, Capone and Drenser on emerging procedures and development of related technologies,” stated Dave Hable, President and CEO of Synergetics USA, Inc. “We are pleased to join forces with Retinal Solutions to develop new instrumentation that leverages their expertise in retinal surgery. Synergetics already manufactures products designed by the surgeons and we are excited about the potential of leveraging their expertise and ideas.” “We believe the combination of Drs. Trese, Capone and Drenser’s experience in retinal surgery combined with our manufacturing and product development capabilities provides the framework to develop new microsurgical products that will have broad applications for retinal surgery,” concluded Mr. Hable. About Synergetics USA, Inc. Synergetics USA, Inc. (“Synergetics USA” or the “Company”) is a leading supplier of precision microsurgery devices. The Company’s primary focus is on the microsurgical disciplines of ophthalmology and neurosurgery. Our distribution channels include a combination of direct and independent sales organizations and important strategic alliances with market leaders. The Company’s product lines focus upon precision engineered, microsurgical, hand-held devices and the delivery of various energy modalities for the performance of less invasive microsurgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency for electrosurgery and oblation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. The Company’s website address is http://www.synergeticsusa.com. Forward-Looking StatementsSome statements in this release may be “forward-looking statements” for the purposes of the Private Securities Litigation Reform Act of 1995.In some cases forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions.Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.These factors, risks and uncertainties are discussed in Synergetics’ Annual Report on Form 10-K for the year ended July 31, 2010, as updated from time to time in our filings with the Securities and Exchange Commission.